Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.48 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.48 |
| ▸ | CTSC | P53634 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | BLM | P54132 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25332799 | 1.00 | CYP1A2 (0.48) | CYP1A2ALOX15GRM2GRM3CTSC | |
| SCHEMBL25843766 | 1.00 | CYP1A2 (0.48) | CYP1A2ALOX15GRM2GRM3CTSC | |
| SCHEMBL1442126 | 0.98 | CYP1A2 (0.50) | CYP1A2ALOX15GRM2GRM3CTSC | |
| SCHEMBL22636233 | 0.98 | CYP1A2 (0.50) | CYP1A2ALOX15GRM2GRM3CTSC | |
| Hydrochloric Acid SCHEMBL27143177 | 0.96 | CYP1A2 (0.48) | CYP1A2ALOX15GRM2GRM3CTSC | |
| Hydrochloric Acid SCHEMBL27143178 | 0.96 | CYP1A2 (0.48) | CYP1A2ALOX15GRM2GRM3CTSC | |
| SCHEMBL22468318 | 0.94 | CYP1A2 (0.50) | CYP1A2ALOX15GRM2GRM3CTSC | |
| SCHEMBL31000663 | 0.90 | CYP1A2 (0.53) | CYP1A2ALOX15GRM2GRM3CTSC | |
| SCHEMBL13837706 | 0.90 | CYP1A2 (0.53) | CYP1A2ALOX15GRM2GRM3CTSC | |
| SCHEMBL17031911 | 0.90 | CYP1A2 (0.53) | CYP1A2ALOX15GRM2GRM3CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| CN-113795249-B | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2025-02-25 | — | — | CN | disclosed |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2024-08-15 | — | — | US | disclosed |
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| WO-2023133174-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| EP-4161902-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-0475184-A1 | Process for the production of peptides by solid phase synthesis | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-03-18 | — | — | EP | disclosed |
| US-4977260-A | Intermediates for preparing mono-, bi- and tricyclic amino acids | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-12-11 | — | — | US | disclosed |
| US-4849524-A | Process of preparing proline derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-07-18 | — | — | US | disclosed |
| US-4822894-A | PURE CIS ENANTIOMERS OF FUSED PYRROLE RING CARBOXYLATES | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-04-18 | — | — | US | disclosed |
| EP-0115345-B1 | PROCESS FOR THE RESOLUTION OF RACEMIC OPTICALLY ACTIVE BICYCLIC IMINO-ALPHA-CARBOXYLIC ACID ESTERS AND USE OF THE COMPOUNDS OBTAINABLE IN THIS WAY FOR THE SYNTHESIS OF CARBOXYALKYL DIPEPTIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-01-07 | — | — | EP | disclosed |
| US-4691022-A | Process for the preparation of monocyclic, bicyclic and tricyclic aminoacids | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-09-01 | — | — | US | disclosed |
| US-4668796-A | Racemates of optically active bicyclic imino-alpha-carboxylic esters | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-05-26 | — | — | US | disclosed |
| US-4558064-A | 2-Azasfiro[4.(3+N)]-3-carboxylic acid derivatives, a process for their preparation, agents containing these derivatives and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-12-10 | — | — | US | disclosed |
| US-4515960-A | INTERMEDIATES FOR HYPOTENSIVES | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-05-07 | — | — | US | disclosed |
| EP-0115345-A1 | Process for the resolution of racemic optically active bicyclic imino-alpha-carboxylic acid esters and use of the compounds obtainable in this way for the synthesis of carboxyalkyl dipeptides | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | C5, CFH, C1QBP | CYP1A2 1838/4885ALOX15 201/4885GRM2 3861/4885 |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | CYP1A2 3323/4885ALOX15 2204/4885GRM2 4656/4885 |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | CYP1A2 2410/4885ALOX15 1749/4885GRM2 4801/4885 |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | CYP1A2 2410/4885ALOX15 1749/4885GRM2 4801/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | CYP1A2 746/4885ALOX15 1455/4885GRM2 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.